Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML

Blood (2022) 140 (Supplement 1): 2002–2004.

https://doi.org/10.1182/blood-2022-159503

Published: 2022

Journal Articles

40% of Females with Mantle Cell Lymphoma Are Managed with Initial Observation: Results from the MCL Biobank Observational Study

Rory McCulloch, FRCPath, MRCP, MBBS, Alexandra Smith, PhD, Brian Wainman, Wendy Ingram, Amelia Lewis, Matthew Hawkins, Nicola Crosbie, Andrew Pettitt, FRCPath, PhD, Simon Rule

Blood (2019) 134 (Supplement_1): 2821.

https://doi.org/10.1182/blood-2019-128340

Published: 2019

Journal Articles

Combined Azacitidine and High Dose Lenalidomide Therapy Is Well Tolerated and Clinically Active in Patients Who Relapse after Allogeneic Stem Cell Transplantation for Actue Myeloid Leukemia: Results of the Uk Trials Acceleration Programme Viola Trial

Charles Craddock, Wendy Ingram, Daniel Slade, Andrea Hodgkinson, BSc(Hons),PhD, Francis J. Mussai, MA, MD DPhil, Carmela De Santo, Jamie Cavenagh, Michael Dennis, MDMRCP,FRCPath, Ram Malladi, MRCP, FRCPath, PhD, Shamyla Siddique, BSc.(Hons.), MPhil, Yap Christina, MSci, PhD CStat

Blood (2017) 130 (Supplement 1): 276.

https://doi.org/10.1182/blood.V130.Suppl_1.276.276

Published: 2017

Journal Articles

Risk Factors for Recurrent CMV Reactivation in CMV Seropositive Recipients Following T Cell Depleted Haematopoietic Stem Cell Transplantation

Abeer Ibrahim, Wendy Ingram, Nicola Price, David Davies, Keith Wilson

Blood (2014) 124 (21): 1134.

https://doi.org/10.1182/blood.V124.21.1134.1134

Published: 2014

Journal Articles

In-Vitro Culture of Human CD80/IL2 Lentivirus Transduced Acute Myeloid Leukemia Cells (AML) Promote NK Cell Activation and Cytolytic Activity

Wendy Ingram, Lucas Chan, Hayrettin Guven, Shahram Kordasti, Linda Barber, Nicola Hardwick, David Darling, Ghulam J Mufti, Farzin Farzaneh

Blood (2008) 112 (11): 2969.

https://doi.org/10.1182/blood.V112.11.2969.2969

Published: 2008

Journal Articles

RFUSIN2 - a Clinical Grade Lentiviral Vector Co-Expressing CD80/IL-2 Manufactured Under GMP for a Phase I Clinical Trial Study of Immune Gene Therapy for Poor Prognosis Acute Myeloid Leukaemia

Lucas Chan, Wendy Ingram, Nicola Hardwick, David Darling, Joti Bhalla, Aytug Kizilors, Shahram Y Kordasti, Ghulam J Mufti, Farzin Farzaneh

Blood (2008) 112 (11): 4630.

https://doi.org/10.1182/blood.V112.11.4630.4630

Published: 2008

Journal Articles

Increased Number of IL-17 Producing CD4 + T Cells in Low Risk Myelodysplastic Syndrome (MDS)

Shahram Y Kordasti, Behdad Afzali, Ziyi Lim, Wendy Ingram, Janet Hayden, Linda Barber, Giovanna Lombardi, Farzin Farzaneh, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath

Blood (2008) 112 (11): 637.

https://doi.org/10.1182/blood.V112.11.637.637

Published: 2008

Journal Articles

CD4 + CD25 high Foxp3 + Regulatory T-Cells Are Correlated with Different Risk Factors in Myelodysplastic Syndrome (MDS).

Shahram Y. Kordasti, MD, Wendy Ingram, MD, Janet Hayden, RCN, David Darling, PhD, Linda Barber, PhD, Farzin Farzaneh, PhD, Ghulam Mufti, MD

Blood (2007) 110 (11): 2445.

https://doi.org/10.1182/blood.V110.11.2445.2445

Published: 2007

Journal Articles

Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes

Azim Mohamedali, Joop Gäken, Natalie A. Twine, Wendy Ingram, Nigel Westwood, Nicholas C. Lea, Janet Hayden, Nora Donaldson, Carlo Aul, Norbert Gattermann, Aristotle Giagounidis, Ulrich Germing, Alan F. List, Ghulam J. Mufti

Blood (2007) 110 (9): 3365–3373.

https://doi.org/10.1182/blood-2007-03-079673

Published: 2007

Includes: Supplemental data

Journal Articles

CD4 + CD25 high Foxp3 + regulatory T cells in myelodysplastic syndrome (MDS)

Shahram Y. Kordasti, Wendy Ingram, Janet Hayden, David Darling, Linda Barber, Behdad Afzali, Giovanna Lombardi, Marcin W. Wlodarski, Jaroslaw P. Maciejewski, Farzin Farzaneh, Ghulam J. Mufti

Blood (2007) 110 (3): 847–850.

https://doi.org/10.1182/blood-2007-01-067546

Published: 2007

Journal Articles

The Pattern of T-Cell Donor Chimerism Is a Key Predictor of Outcome Following Alemtuzumab Based Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation for MDS and AML.

ZiYi Lim, Laurence Pearce, Aloysius Y.L. Ho, Linda Barber, Wendy Ingram, Monica Usai, Stephen Devereux, Antonio Pagliuca, Ghulam Mufti

Blood (2006) 108 (11): 42.

https://doi.org/10.1182/blood.V108.11.42.42

Published: 2006

Journal Articles

Kinesin Family Member 20A (KIF20A) Is Specifically down Regulated in 5q- CD34+ and CD61+ Cells and Uniparental Disomy Is Not a Feature of 5q- Syndrome.

Nicholas C. Lea, PhD, Azim Mohamedali, PhD, Natalie Twine, MSc, Joop Gaken, Phd, Nigel Westwood, Phd, Wendy Ingram, MBBS, Ghulam Mufti, MD

Blood (2006) 108 (11): 2611.

https://doi.org/10.1182/blood.V108.11.2611.2611

Published: 2006

Journal Articles

Expansion of Polyclonal CD4 + CD25 high Foxp3 + Regulatory T-Cells in High Risk Myelodysplastic Syndromes (MDS).

Shahram Y. Kordasti, MD, Wendy Ingram, MD, Janet Hayden, RN, David Darling, PhD, Linda Barber, PhD, Farzin Farzaneh, PhD, Ghulam J. Mufti, MD

Blood (2006) 108 (11): 2641.

https://doi.org/10.1182/blood.V108.11.2641.2641

Published: 2006

Journal Articles

Co-Morbidity and Disease Status at the Time of Transplant Predict Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) for Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML).

Wendy Ingram, MD, Zi Y. Lim, MD, Michelle Kenyon, RN, Stephen Devereux, MD, Antonio Pagliuca, MD, Aloysius Y.L. Ho, MD, Mufti Ghulam, MD

Blood (2006) 108 (11): 3108.

https://doi.org/10.1182/blood.V108.11.3108.3108

Published: 2006

Journal Articles

Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation Is as Effective in Poor Risk as Standard Risk Acute Myeloid Leukaemia (AML).

Wendy Ingram, Ziyi Lim, Antonio Pagliuca, Stephen Devereux, Aloysius Ho, Ghulam Mufti

Blood (2005) 106 (11): 2901.

https://doi.org/10.1182/blood.V106.11.2901.2901

Published: 2005

Journal Articles

Use of Pre-Emptive Donor Lymphocyte Infusions To Achieve Durable Remission Following Alemtuzumab Based Reduced Intensity Conditioning (RIC) Transplantation for AML or MDS.

ZiYi Lim, Laurence Pearce, Wendy Ingram, Rafael Duarte, Stephen Devereux, Antonio Pagliuca, Aloysius Ho, Ghulam Mufti

Blood (2005) 106 (11): 1124.

https://doi.org/10.1182/blood.V106.11.1124.1124

Published: 2005

Journal Articles

Improved Disease Free Survival Following Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation Incorporating Alemtuzumab Compared with Autologous Stem Cell Transplantation in Follicular Lymphoma.

Wendy Ingram, Stephen Devereux, Juan Gonzalez, Aloysius Ho, Ghulam Mufti, Antonio Pagliuca

Blood (2005) 106 (11): 1144.

https://doi.org/10.1182/blood.V106.11.1144.1144

Published: 2005

Journal Articles

Clonal Gammopathies Following Reduced Intensity Conditioning Transplantation with Fludarabine, Busulphan and Alemtuzumab for Myeloid Malignancies Predict Improved Overall Survival.

ZiYi Lim, Antonio Pagliuca, Wendy Ingram, Dragana Milojkovic, Mojtaba Akthari, Aloysius Ho, Stephen Devereux, Rafael Duarte, Ghulam J. Mufti

Blood (2005) 106 (11): 1410.

https://doi.org/10.1182/blood.V106.11.1410.1410

Published: 2005

Journal Articles

Clonal Gammopathies, Immune Cytopenias and Autoimmune Thyroid Dysfunction Following Alemtuzumab Containing Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation.

Mojtaba Akhtari, Kavita Raj, Wendy Ingram, Dragana Milojkovic, Ihab El-Hemaidi, Stephen Devereux, Antonio Pagliuca, Aloysius Ho, Ghulam Mufti

Blood (2004) 104 (11): 1839.

https://doi.org/10.1182/blood.V104.11.1839.1839

Published: 2004

NARROW

High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML

40% of Females with Mantle Cell Lymphoma Are Managed with Initial Observation: Results from the MCL Biobank Observational Study

Combined Azacitidine and High Dose Lenalidomide Therapy Is Well Tolerated and Clinically Active in Patients Who Relapse after Allogeneic Stem Cell Transplantation for Actue Myeloid Leukemia: Results of the Uk Trials Acceleration Programme Viola Trial

Risk Factors for Recurrent CMV Reactivation in CMV Seropositive Recipients Following T Cell Depleted Haematopoietic Stem Cell Transplantation

In-Vitro Culture of Human CD80/IL2 Lentivirus Transduced Acute Myeloid Leukemia Cells (AML) Promote NK Cell Activation and Cytolytic Activity

RFUSIN2 - a Clinical Grade Lentiviral Vector Co-Expressing CD80/IL-2 Manufactured Under GMP for a Phase I Clinical Trial Study of Immune Gene Therapy for Poor Prognosis Acute Myeloid Leukaemia

Increased Number of IL-17 Producing CD4 + T Cells in Low Risk Myelodysplastic Syndrome (MDS)

CD4 + CD25 high Foxp3 + Regulatory T-Cells Are Correlated with Different Risk Factors in Myelodysplastic Syndrome (MDS).

Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes

CD4 + CD25 high Foxp3 + regulatory T cells in myelodysplastic syndrome (MDS)

The Pattern of T-Cell Donor Chimerism Is a Key Predictor of Outcome Following Alemtuzumab Based Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation for MDS and AML.

Kinesin Family Member 20A (KIF20A) Is Specifically down Regulated in 5q- CD34+ and CD61+ Cells and Uniparental Disomy Is Not a Feature of 5q- Syndrome.

Expansion of Polyclonal CD4 + CD25 high Foxp3 + Regulatory T-Cells in High Risk Myelodysplastic Syndromes (MDS).

Co-Morbidity and Disease Status at the Time of Transplant Predict Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) for Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML).

Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation Is as Effective in Poor Risk as Standard Risk Acute Myeloid Leukaemia (AML).

Use of Pre-Emptive Donor Lymphocyte Infusions To Achieve Durable Remission Following Alemtuzumab Based Reduced Intensity Conditioning (RIC) Transplantation for AML or MDS.

Improved Disease Free Survival Following Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation Incorporating Alemtuzumab Compared with Autologous Stem Cell Transplantation in Follicular Lymphoma.

Clonal Gammopathies Following Reduced Intensity Conditioning Transplantation with Fludarabine, Busulphan and Alemtuzumab for Myeloid Malignancies Predict Improved Overall Survival.

Clonal Gammopathies, Immune Cytopenias and Autoimmune Thyroid Dysfunction Following Alemtuzumab Containing Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only